<DOC>
	<DOC>NCT02458183</DOC>
	<brief_summary>The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.</brief_summary>
	<brief_title>Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS</brief_title>
	<detailed_description>A multinational, multicenter, randomized, comparative, open-label, phase 3 study Primary Objective: To assess the vaccine response rates after the three-dose primary vaccination Secondary Objectives: To measure the antibody titer after the three-dose primary vaccination and to assess the safety of the investigational products</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study. Male and female infants reaching at least 7 weeks of age on the day of first dose of investigational product. Male and female infants who are identified to be healthy based on physical examination and medical history. Subjects who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the day of vaccination. Subjects who have moderate or severe acute disease (regardless of fever). Subjects who have any history of diphtheria, tetanus, pertussis, or poliomyelitis. Subjects who have major congenital defects. Subjects who show any evidence of continuous hematologic, hepatic, cardiac, renal, or respiratory disease. Subjects who have abnormalities in the immune system, or congenital/acquired immune deﬁciency. Subjects who received immunosuppressive dose of systemic corticosteroids therapy within 30 days before the vaccination. Subjects who are likely to have adverse side effects on central nervous system because of the subjects' family history of genetic diseases in central nervous system such as progressive neurological problems or epilepsy. Subjects who are allergic to the ingredients of the investigational products. Subjects who have received immunoglobulins or blood products or plan to get those medications. Subjects who have received vaccines other than those allowed in the protocol or plan to get those prohibited vaccines during the study period. Subjects who are currently participating or planning to participate in other clinical studies during the study period. Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.</criteria>
	<gender>All</gender>
	<minimum_age>7 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>